At its Oct. 12, 2026 semiannual results briefing, Zhijiang Biological said overseas markets are a strategic priority. In 1H2026 the company secured seven new international certifications. With ongoing deliveries of overseas orders, expanded CE/FDA coverage and deeper distribution channels, it expects overseas revenue to increase gradually, targeting Europe, Africa, the Middle East and Southeast Asia.

China International Capital Co research says 1H 2026 A-share tech growth was driven by AI supply chain and high-end manufacturing, sustaining a structural rally. Since July, rising negative narratives around the global AI chain, expectations of tighter overseas liquidity and increased Middle East geopolitical risk have triggered a notable correction in previously strong growth sectors. With growth-style volatility higher and risk appetite weaker, the firm recommends re-evaluating the relative allocation to dividend-paying assets. Given limited aggregate growth elasticity alongside pockets of structural high growth and elevated risk-off swings, a "technology + dividends" dumbbell allocation is seen as a way to balance earnings growth potential, shareholder cash returns and portfolio stability. For implementation, it advises targeting tech names with clear industry trends, durable competitive advantages and demonstrated earnings delivery; and dividend names with stable earnings and cash flow, sustainable payout policies and reasonable valuations.

Ukrainian President Zelenskiy said Russia launched more than 200 attacks on Ukraine's power generation and transmission facilities in one week.